Novel approaches for targeted cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Chemotherapy faces challenges like lack of selectivity, leading to severe side effects and drug resistance in cancer treatment.
• Tumor markers, particularly growth factor receptors overexpressed on cancer cells, present viable targets for selective cancer therapy.
• Targeted delivery of cytotoxic agents, an old concept, is being revitalized by new understanding of targeted therapy mechanisms.

Purpose of the Study:

• To review current developments in selective targeting strategies for growth factor receptor-overexpressing tumors.
• To explore methods for overcoming drug resistance in cancer management through targeted approaches.
• To highlight advancements in therapeutic interventions focusing on specific tumor markers.

Main Methods:

• Review of pharmacological agents designed for selective targeting of growth factor receptors.
• Analysis of various therapeutic modalities including monoclonal antibodies, small molecules, and drug conjugates.
• Examination of strategies to bypass or overcome drug resistance in targeted cancer therapy.

Main Results:

• Numerous targeted agents, including monoclonal antibodies and small molecule inhibitors, have been developed to block growth factor receptor action.
• Diverse delivery systems such as immunoliposomes and antibody-drug conjugates enhance targeted delivery and efficacy.
• Emerging strategies show promise in overcoming resistance mechanisms associated with targeted therapies.

Conclusions:

• Selective targeting of growth factor receptors holds significant potential for improving cancer treatment efficacy and reducing toxicity.
• Continued research into novel targeted agents and drug delivery systems is crucial for advancing cancer therapy.
• Bypassing drug resistance through innovative targeting strategies is key to long-term patient benefit in managing receptor-overexpressing tumors.